But_home
But_blogshome
But_forum
Icon_rss_infobarSubscribe to receive updates
on new articles and posts from this blog.
 

RE-LY: Patient preference based on the data


Our academic colleagues and trialists prepare and execute trials to evaluate MACE and safety. Critical of course, but after the trial is over practioners need to assess the practical aspects of therapies which include non-MACE considerations like patient nuisance factors: diet restrictions, venipuncture cost and discomfort, and difficulty in reversing anticoagulation. If you needed oral anticoagulation with atrial fibrillation would you prefer warfarin over dabigatran?

See:
RE-LY: Oral antithrombin dabigatran outshines warfarin in atrial fib
Best of Barcelona: PLATO and RE-LY
RE-LY: An obituary for Warfarin?
Dabigatran versus Warfarin in Patients with Atrial Fibrillation

 

CommentsCommentaires

Add your own commentsFaire un commentaire





 



About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.

Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.

Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:

  • Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
  • Practice approaches to the extra clinical issues in dealing with managed care insurers
  • Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
  • Experiences with restrictions on testing and imaging
The video blog (VLOG) will provide an opportunity to share broadly different approaches to the common conundrums we face in caring for patients. My hope is that this forum will provide useful data points for practice outside of tertiary and academic centers and a look inside community hospitals and physician’s practice patterns in the office, starting with mine.